

Anti-coagulant use pre prostate biopsy

Drug	Stop medication Yes/No	When to stop?	Level of Evidence
Warfarin (Coumadin)	Yes	5-7 days	1a ¹
Heparin	Yes	3-5 hours	1a ¹
Rivaroxaban (Xarelto)	Yes	48 hours	1a ¹
Dabigatran (Pradaxa)	Yes	48 hours	1a ¹
Apixaban (Eliquis)	Yes	48 hours	1a ¹
Edoxaban (Savaysa)	Yes	48 hours	1a ¹
Enoxaparin (Lovenox)	Yes	6 hours	1a ¹
Fondaparinux (Arixtra)	Yes	48 hours	1a ¹

Reference

1. Culkun DJ, Exaire EJ, Green D, et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol 2014;192:1026-34. <http://www.aunet.org/guidelines/anticoagulation-and-antiplatelet-therapy>

This table is taken from

C. Tillier, P. Cornford, G. De Lauw, et al. Transrectal Ultrasound Guided Biopsy of the Prostate – Evidence-based Guidelines for Best Practice in Urological Health Care. 1st ed.

Arnhem, The Netherlands: EAUN Office; 2019. ISBN 978-94-926-71066. www.eaun.uroweb.org

Patients on anti-aggregant therapy for secondary stroke prevention, especially after a recent stroke, should continue with aspirin. Withdrawal of anti-aggregants should be avoided within 12 months of patients undergoing drug-eluting or bare-metal stent placement. Patients in the high-risk group, may require a bridging treatment to their anti-coagulant therapy. Discuss with the patient's prescriber.

Anti-aggregant* use pre prostate biopsy

Drug	Stop medication Yes/No	When to stop?	Level of Evidence
Aspirin	No	N/A	1b ^{2,3,4}
Clopidogrel (Plavix)	Yes	7 days	1a ^{1,3}
Prasugrel (Efient)	Do not stop this medication without consulting the prescriber	7 days	1a ⁵
Dipyridamole/aspirin (Aggrenox)	Yes	3 days	1a ¹
Ticlopidine (Ticlid)	Yes	7 days	1a ⁶
Eptifibatide (Integrilin)	Yes	2-4 hours	According pharmacology ⁷
Ticagrelor (Brilinta)	Do not stop this medication without consulting the prescriber	3 days	According pharmacology ⁷
Rivaroxaban or Apixaban	Yes	2 days	1a ¹

**Also known as anti-platelets*

Patients who have had recent or recurrent TIA/stroke should be considered high risk; therefore, advice on stopping medication should be sought from the patient's prescriber.

References

1. Culkin DJ, Exaire EJ, Green D, et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol 2014;192:1026-34.
2. Kariotis I, Philippou P, Volanis D, et al. Safety of ultrasound-guided transrectal extended prostate biopsy in patients receiving low-dose aspirin. Int Braz J Urol 2010;36:308-16.
3. Chowdhury R, Abbas A, Idriz S, et al. Should warfarin or aspirin be stopped prior to prostate biopsy? An analysis of bleeding complications related to increasing sample number regimes. Clin Radiol 2012;67:e64-70.
4. Raheem OA, Casey RG, Lynch TH. Does anticoagulant or antiplatelet therapy need to be discontinued for transrectal ultrasound-guided prostate biopsies? A systematic literature review. Curr Urol 2011;5:121-4.
5. Price MJ, Walder JS, Baker BA, et al. Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease. J Am Coll Cardiol 2012;59:2338-43.
6. Billett HH. Antiplatelet Agents and Arterial Thrombosis. Cardiol Clin 2008;26:189-201.
7. Oprea AD, Popescu WM. Perioperative management of antiplatelet therapy. Br J Anaesth 2013;111:i3-17.